(Reuters) – The European Union’s drug regulator will this week consider wider use of Novo Nordisk’s weight-loss drug Wegovy to include reducing the risk of strokes and heart attacks. Approval could help the Danish drugmaker better argue its case for making the drug available via public sector health systems in Europe. (Read More)